More on RNAC

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-114.7% Growth)
- Ratings (8.8 Score)

Upcoming Events

- Earnings (8/7/26 *Est.)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Cartesian Therapeutics (NQ:RNAC)
Delayed: 6.27 -0.14 (2.18%)
Prev. Close $6.41  
Open$6.43 
52 Wk High$ 
52 Wk Low$ 
Day High$6.62 
Day Low$6.19 
P/E N/A  
EPS$ 
Volume172,079 


Jun 2, 2026 04:07 PM Form 144 Cartesian Therapeutics, Filed by: Miljkovic Milos
May 26, 2026 10:48 AM Mizuho on Cartesian Therapeutics (RNAC): 'We believe the potential of Descartes-08 remains underappreciated'
May 26, 2026 07:09 AM Form 8-K Cartesian Therapeutics, For: May 22
May 26, 2026 07:00 AM Cartesian Therapeutics secures $150 million credit facility from K2 HealthVentures
May 26, 2026 07:00 AM Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
May 12, 2026 07:01 AM Cartesian Therapeutics to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 12, 2026 06:50 AM Cartesian Therapeutics (RNAC) PT Lowered to $25 at H.C. Wainwright
May 6, 2026 11:07 AM Form SCHEDULE 13G/A Cartesian Therapeutics, Filed by: FMR LLC
May 4, 2026 07:05 AM Cartesian Therapeutics Announces New Employment Inducement Grants
Apr 30, 2026 07:33 AM Cartesian Therapeutics (RNAC) Misses Q1 EPS by 146c
View All Articles

Entities mentioned with RNAC

View All Entities